

**FRUZAQLA  
(fruquintinib)**

**Pre - PA Allowance**

None

---

**Prior-Approval Requirements**

**Age** 18 years of age or older

**Diagnosis**

Patient must have the following:

Metastatic colorectal cancer (mCRC)

**AND ALL** of the following:

- Patient has previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy
- Patient has previously been treated with an anti-VEGF therapy
- If RAS wild-type and medically appropriate, patient has previously been treated with an anti-EGFR therapy
- Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Fruzaqla and for 2 weeks after the last dose
- Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Fruzaqla and for 2 weeks after the last dose

**Prior - Approval Limits**

**Quantity**

Strength	Quantity
1 mg	252 capsules per 84 days <b>OR</b>
5 mg	63 capsules per 84 days

**Duration** 12 months

---

**Prior – Approval *Renewal* Requirements**

**Age** 18 years of age or older

**Diagnosis**



**BlueCross  
BlueShield**

Federal Employee Program.

**FRUZAQLA  
(fruquintinib)**

Patient must have the following:

Metastatic colorectal cancer (mCRC)

**AND ALL** of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Fruzaqla and for 2 weeks after the last dose
- c. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Fruzaqla and for 2 weeks after the last dose

**Prior - Approval *Renewal* Limits**

Same as above